LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "meropenem vaborbactam" as a keyword



Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

Sign Up to like & get
recommendations! Published in 2020 at "Pediatric Pulmonology"

DOI: 10.1002/ppul.24945

Abstract: Cystic fibrosis is associated with significant morbidity and early mortality due to recurrent acute and chronic lung infections. The chronic use of multiple antibiotics without pathogen eradication increases the possibility of extensive drug resistance or… read more here.

Keywords: cefiderocol meropenem; cystic fibrosis; drug; meropenem vaborbactam ... See more keywords
Photo by cdc from unsplash

Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem‐vaborbactam and cefiderocol

Sign Up to like & get
recommendations! Published in 2021 at "Pediatric Pulmonology"

DOI: 10.1002/ppul.25552

Abstract: We are writing this letter to provide an update of published information on antibiotics for cystic fibrosis (CF) pulmonary exacerbations to the State of the Art articles by Zobell et al. Information on meropenem‐vaborbactam and… read more here.

Keywords: cystic fibrosis; meropenem vaborbactam; pulmonary exacerbations; vaborbactam cefiderocol ... See more keywords

Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations

Sign Up to like & get
recommendations! Published in 2017 at "Drugs"

DOI: 10.1007/s40265-017-0851-9

Abstract: Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as… read more here.

Keywords: imipenem; vaborbactam; imipenem relebactam; meropenem vaborbactam ... See more keywords
Photo by enginakyurt from unsplash

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

Sign Up to like & get
recommendations! Published in 2022 at "Expert Review of Anti-infective Therapy"

DOI: 10.1080/14787210.2022.2030219

Abstract: ABSTRACT Introduction The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin. Areas covered The search terms ‘meropenem-vaborbactam’ or… read more here.

Keywords: vaborbactam critical; meropenem; critical positioning; positioning management ... See more keywords
Photo by chrostek from unsplash

In vitro susceptibility of carbapenem resistant Enterobacterales to meropenem-vaborbactam and ceftazidime-avibactam at a single academic medical centre

Sign Up to like & get
recommendations! Published in 2023 at "Infectious Diseases"

DOI: 10.1080/23744235.2023.2177337

Abstract: Abstract Background Carbapenem-resistant Enterobacterales (CRE) are considered an urgent threat. Ceftazidime-avibactam and meropenem-vaborbactam contain β-lactamase inhibitors active against CRE isolates including those that produce Klebsiella pneumoniae carbapenemases (KPC). Methods Retrospective chart review of CRE isolates… read more here.

Keywords: carbapenem resistant; resistant enterobacterales; meropenem vaborbactam; ceftazidime avibactam ... See more keywords
Photo by satheeshsankaran from unsplash

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Sign Up to like & get
recommendations! Published in 2020 at "Open Forum Infectious Diseases"

DOI: 10.1093/ofid/ofaa051

Abstract: Abstract Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30… read more here.

Keywords: serious gram; patients treated; gram negative; negative bacterial ... See more keywords
Photo by louishansel from unsplash

Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate

Sign Up to like & get
recommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"

DOI: 10.1128/aac.00191-22

Abstract: Herein, we report the in vivo evolution of imipenem/relebactam-resistance in KPC-producing K. pneumoniae (KPC-Kp) isolated from a critically-ill patient treated with multiple combination therapies based on ceftazidime-avibactam or meropenem-vaborbactam. Imipenem/relebactam-resistance was associated to meropenem-vaborbactam cross-resistance… read more here.

Keywords: meropenem vaborbactam; imipenem relebactam; copy; resistance ... See more keywords
Photo by gabiontheroad from unsplash

Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae

Sign Up to like & get
recommendations! Published in 2020 at "Antimicrobial Agents and Chemotherapy"

DOI: 10.1128/aac.00409-20

Abstract: Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae isolates. Recently, this has driven clinical deployment of the β-lactam–β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam. We show that four steps, i.e., ompK36 and ramR… read more here.

Keywords: four steps; meropenem vaborbactam; resistance; klebsiella pneumoniae ... See more keywords
Photo from wikipedia

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae

Sign Up to like & get
recommendations! Published in 2017 at "Antimicrobial Agents and Chemotherapy"

DOI: 10.1128/aac.01446-17

Abstract: ABSTRACT Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae. The objective of these studies was to evaluate the efficacy of meropenem alone and in combination with vaborbactam in… read more here.

Keywords: vaborbactam; meropenem vaborbactam; meropenem; carbapenem resistant ... See more keywords
Photo by sharonmccutcheon from unsplash

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

Sign Up to like & get
recommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"

DOI: 10.1128/aac.02103-17

Abstract: ABSTRACT Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem. The pharmacokinetics of the combination… read more here.

Keywords: meropenem vaborbactam; impairment; subjects chronic; dose ... See more keywords
Photo by ggfujyoj from unsplash

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints

Sign Up to like & get
recommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"

DOI: 10.1128/aac.02130-21

Abstract: Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken using population pharmacokinetic models, nonclinical PK-PD targets for… read more here.

Keywords: meropenem; attainment analyses; target attainment; dosing regimens ... See more keywords